In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline
W idespread resistance to antibiotics, including resistance to the older tetracyclines (tetracycline, doxycycline, and minocycline), has limited their usefulness in recent years (1, 2) . New tetracycline derivatives that inhibit resistant organisms have been approved or are in development, including the glycylcyclines and specifically tigecycline, and fluorocyclines, including eravacycline (TP-434), and both tigecycline and eravacycline have potent Grampositive and Gram-negative in vitro activity (3) (4) (5) (6) . The discovery of the 9-aminomethyl class of tetracyclines has led to the identification of omadacycline (PTK 0796) that is poised to begin phase 3 clinical trials in acute bacterial skin and skin structure infections (ABSSSI), community-acquired (CA) bacterial pneumonia (CABP), and urinary tract infections (UTI) with both an intravenous (i.v.) and oral tablet formulation. Omadacycline, (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-9{[(2,2-dimethylpropyl)amino]methyl}-3, 10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, contains a four-ring carbocyclic skeleton and is a semisynthetic compound prepared by chemical modification of minocycline ( Fig. 1) (7, 8) .
Omadacycline is distinct from older tetracyclines because it demonstrates in vitro activity against a relatively broad spectrum of organisms, including Gram-positive, Gram-negative, anaerobic, and atypical pathogens, and demonstrates similar in vitro activity against pathogens that express not only tetracycline resistance but resistance to other antibiotics, including methicillin, vancomycin, erythromycin, and ciprofloxacin (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . This broad in vitro activity has been confirmed in various in vivo models of infection (21) (22) (23) (24) . Omadacycline is bioavailable in humans by both oral and intravenous routes and does not demonstrate significant gastrointestinal side effects (25) (26) (27) (28) . The targeted indications encompass acute bacterial infections where a broad-spectrum antibiotic with activity against the most prevalent community-acquired multidrug-resistant organisms is desired. This report is the initial description of the in vitro spectrum and in vivo efficacy of omadacycline. The in vitro activity of omadacycline translates into potent in vivo efficacy in a lethal infection model, suggesting that the pharmacodynamic requirements necessary for human clinical trial investigation can be achieved. (18) .
MATERIALS AND METHODS

Bacterial
PCR for detection and identification of tetracycline resistance genes. The presence of the efflux genes tet(K) and tet(L), as well as tet(A), tet (B) , and genes of the ribosomal protection (RP) family [tet(M), tet(O), and tet(S)] was assessed by multiplex PCR (29) .
Systemic i.p. challenge model. Six-week-old, specific-pathogen-free, male CD-1 mice, weighing 18 to 30 g (Charles River, Wilmington, MA), were used for all experiments. Animals were acclimated for 1 week following delivery. Mice were allowed food and water ad libitum and kept in a constant 12-h light/dark cycle. Bacterial cultures were grown by either streaking frozen colonies onto tryptic soy agar II plates with 5% sheep's blood (Northeast Laboratories, Waterville, ME) and incubating them overnight in a CO 2 enriched environment at 37°C (S. pneumoniae) or growing frozen isolates in a 37°C shaker at 180 rpm in Mueller-Hinton broth (Northeast Labs, Waterville, ME) (for S. aureus and E. coli). For S. pneumoniae, following the overnight incubation, the colonies were aseptically collected from two to three agar plates and resuspended in 3 ml of sterile phosphate-buffered saline (PBS) (Fisher Scientific, Boston, MA) for a final concentration of approximately 1 ϫ 10 9 CFU/ml. For S. aureus and E. coli strains, an overnight broth was grown to a concentration of approximately 1 ϫ 10 9 CFU/ml. Serial dilutions of all bacterial suspensions were performed in sterile PBS to obtain the infectious dose used for individual experiments. Infectious doses used in each experiment were confirmed by plating serial dilutions on tryptic soy agar II plates with 5% sheep's blood and incubating plates overnight (in a CO 2 enriched environment for S. pneumoniae) at 37°C, after which bacterial colonies were then enumerated. Septicemia was induced by infecting mice intraperitoneally (i.p.) with 500 l containing (6. ) with omadacycline or comparator compounds of interest, dissolved in sterile saline for injection at a volume of 10 ml/kg. All drug doses were formulated fresh immediately prior to administration and adjusted to account for percent activity. A minimum of four dose levels were tested per experiment with 5 mice/group. The typical doses tested ranged from 0.11 to 18 mg/kg of body weight, with exceptions for comparators that required significantly higher or lower doses to achieve 50% efficacy (dose range minimum-maximum, 0.08 to 54 mg/ kg). Each study also included an untreated control group. Mice were housed in filter-topped cages in an isolated room and monitored for morbidity at least every 24 h for 7 days. Efficacy was determined by calculating the 50% effective dose (ED 50 ) for all drugs tested. The ED 50 is defined as the dose required to achieve 50% survival at 7 days p.i. and was estimated when possible using the formula y ϭ 1/[1 ϩ 10 (log(k)-log(x)ϫ 4.
2) ], where k ϭ 0.5, by nonlinear regression analysis with Prism, version 3.0 software. All animal protocols were critically reviewed and approved by the Paratek Pharmaceuticals, Inc., Institutional Animal Care and Use Committee. Table 1 ). The concentration of omadacycline required to inhibit growth of several strains of E. coli carrying efflux genes [tet(A)] was also reduced compared to conventional tetracyclines.
RESULTS
MICs of omadacycline, tetracycline, and doxycycline on characterized tetracycline-resistant Gram-positive and Gram-negative bacteria. Omadacycline demonstrated activity against the Gram-positive pathogens S. aureus, Enterococcus faecalis, Enterococcus faecium, S. pneumoniae, and beta-hemolytic streptococci carrying ribosomal protection [tet(M), tet(O), and tet(S)] and efflux [tet(K) and tet(L)] tetracycline resistance genes (
Omadacycline demonstrates in vitro activity against a broad panel of clinically relevant Gram-positive and Gram-negative bacterial strains. The comparative in vitro activity of omadacycline was assessed against a broad panel of clinically significant Gram-positive and Gram-negative bacteria. Omadacycline was as active as comparators against susceptible S. aureus and was more active than most comparators against MRSA strains, most of which were resistant to more than one comparator antibiotic (Table 2). These results indicate that omadacycline specifically overcomes the problem of tetracycline, doxycycline, and minocycline resistance in S. aureus.
One of the more difficult to treat pathogens, and the pathogen that has been the most problematic in terms of resistance to antibiotics, is the genus Enterococcus, including both Enterococcus faecalis and Enterococcus faecium. Isolates of both species have acquired mechanisms of resistance to vancomycin, and such strains present a difficult therapeutic challenge. Omadacycline is active against both species and is equally active against vancomycin-susceptible and -resistant isolates (Table 2) . Omadacycline is also equally active against tetracycline-resistant and -susceptible isolates of E. faecalis and E. faecium.
S. pneumoniae is an important respiratory pathogen in the hospital and community. Of particular concern in the community are isolates resistant to accepted oral antibiotics, particularly penicillins and cephalosporins, macrolides, and tetracyclines. Omadacycline exhibits activity against all S. pneumoniae isolates tested, regardless of resistance to these agents and even when isolates are resistant to multiple antibiotics (tetracycline plus penicillin plus azithromycin) ( Table 2) .
Omadacycline also exhibits in vitro activity against other strep- tococci. Streptococcus pyogenes (Lancefield group A, beta-hemolytic streptococcus) and Streptococcus agalactiae (Lancefield group B, beta-hemolytic streptococcus) are susceptible to omadacycline (Table 2) . Finally, omadacycline exhibits activity in vitro against some Gram-negative bacteria including E. coli, Klebsiella pneumoniae, and Haemophilus influenzae (Table 3) .
Comparative efficacy studies in the in vivo systemic infection model. The efficacy of omadacycline was tested in a systemic infection model to determine if omadacycline has potential as a clinical therapy in humans. The i.p. challenge model is a standard in vivo model of systemic infection commonly used as a basic screening tool to evaluate the antibiotic potential of novel therapies (30) .
Omadacycline has demonstrated favorable pharmacokinetics intravenously in multiple species and has demonstrated good intravenous and oral bioavailability in humans (27, 28, 31) . Omadacycline is currently being developed as both an intravenous and oral broad-spectrum clinical therapy (25, 26, 32) . However, the oral bioavailability of omadacycline in rodents is significantly lower, as demonstrated by pharmacokinetic evaluation and subsequent efficacy studies (data not shown). Because murine omadacycline bioavailability is particularly poor compared to the good oral bioavailability previously observed in other nonrodent species and humans, in vivo efficacy studies in mice were conducted by administering omadacycline intravenously.
A single i.v. dose of omadacycline demonstrated potent efficacy against tetracycline-sensitive and tetracycline-resistant strains of S. pneumoniae and S. aureus, as well as proving efficacious against the common Gram-negative pathogen E. coli, in the murine systemic i.p. challenge model (Table 4) . Efficacy was evaluated by determining the ED 50 s for omadacycline and each comparator antibiotic. Against the highly virulent, mucoid, tetracycline-sensitive S. pneumoniae PBS1339 strain, the ED 50 of 3.34 mg/kg for omadacycline was similar to that of the glycycline, tigecycline (4.13 mg/kg). Omadacycline was over 4 to 5 times more efficacious than doxycycline, vancomycin, and levofloxacin and over 7 times more efficacious than linezolid (with ED 50 s of 14.23 mg/kg, 15.7 mg/kg, 19.35 mg/kg, and 24.47 mg/kg, respectively). Ceftriaxone and daptomycin were slightly more potent than omadacycline (1.10 mg/kg and 1.43 mg/kg, respectively).
Against the tetracycline-resistant, azithromycin-resistant Tet M S. pneumoniae 700905 strain, the ED 50 for omadacycline (0.45 mg/kg) was lower than that of all the other comparators tested. Omadacycline was over 30 times more active than linezolid (13.88 mg/kg) and slightly more efficacious than vancomycin (0.91 mg/ kg) and tigecycline (1.72 mg/kg). Doxycycline failed to demonstrate any efficacy even at the highest dose tested (54 mg/kg); thus, an ED 50 value could not be calculated.
The ED 50 of 1.10 mg/kg for omadacycline was lower than that of all the other antibiotics tested against the tetracycline-sensitive S. pneumoniae 157E-2 strain. The efficacy of omadacycline was similar to that of doxycycline (1.55 mg/kg) and tigecycline (1.72 mg/kg), but omadacycline was over 11 times more active than vancomycin (12.32 mg/kg). Linezolid failed to protect the mice at the highest dose tested (27 mg/kg); thus, an ED 50 value could not be calculated.
In the tetracycline-sensitive S. aureus 29213 i.p. challenge model, omadacycline was more than 3 to 5 times more potent than vancomycin and linezolid (1.74 mg/kg versus 6.09 mg/kg and 9.91 mg/kg, respectively) but was slightly less effective than doxycycline and tigecycline (0.91 mg/kg and 0.73 mg/kg, respectively). Against the clinical MRSA Tet K, Tet 38 S. aureus USA300 strain, omadacycline had an ED 50 of 0.90 mg/kg and was over 9 times more active than linezolid (8.18 mg/kg). Omadacycline was over 4 times more potent than doxycycline (4.13 mg/kg) but slightly less potent than tigecycline (0.58 mg/kg). Vancomycin failed at all the doses tested including 18 mg/kg; thus, an ED 50 could not be accurately calculated.
A single i.v. dose of omadacycline resulted in an ED 50 of 0.45 mg/kg against the tetracycline-sensitive clinical S. aureus USA400 strain. Omadacycline was more efficacious than any of the other comparators tested. Omadacycline was twice as active as doxycycline and tigecycline (1.12 mg/kg and 1.09 mg/kg, respectively) and 7 and 18 times more effective, respectively, than vancomycin and linezolid (3.29 mg/kg and 8.12 mg/kg, respectively).
Omadacycline also had a lower ED 50 than any of the other comparators tested against the MRSA Tet M S. aureus MRSA5 strain. With an ED 50 of 0.30 mg/kg, omadacycline was over 5 times more efficacious than tigecycline (1.74 mg/kg) and over 80 times more active than linezolid (24.53 mg/kg). Neither vancomycin nor doxycycline demonstrated efficacy at the highest doses tested (18 mg/kg and 54 mg/kg, respectively).
With an ED 50 of 2.02 mg/kg, omadacycline also demonstrated in vivo efficacy against the Gram-negative bacteria, tetracyclinesensitive E. coli PBS1478. Although omadacycline was not as potent as ciprofloxacin (0.07 mg/kg), a single i.v. dose of omadacy- Omadacycline is metabolically stable and has demonstrated low protein binding across all concentrations and species tested (36) . In a phase 1 oral absorption, distribution, metabolism, and excretion (ADME) study, no metabolites of omadacycline were isolated, and balanced elimination via the gut and urinary systems and a high concentration of omadacycline were detected in urine (27) . These data support further consideration of clinical trial testing in patients with urinary tract infections. In a phase 2 study of patients with complicated skin and soft tissue infections, oral and i.v. omadacycline was well tolerated, with efficacy demonstrating comparability with the comparator linezolid. These data support further clinical trial investigation in skin and soft tissue infections (37) .
Antimicrobial resistance continues to grow while the remaining effective antibiotic arsenal continues to diminish. Staphylococci including methicillin-resistant S. aureus, enterococcus including vancomycin-resistant E. faecalis and E. faecium, and pneumococcus including penicillin and multidrug-resistant S. pneumoniae remain problems in the community and the hospital, with limited treatment options (38) (39) (40) (41) (42) (43) . Omadacycline is capable of overcoming multiple mechanisms of tetracycline resistance as well as of maintaining efficacy against the tetracycline-susceptible strains, as demonstrated both in vitro and in vivo. Omadacycline may be an important and desirable treatment alternative for patients with community-acquired infections where the epidemiology suggests a problematic prevalence of resistant pathogens. Our data support the clinical evaluation of intravenous and oral treatment with omadacycline for multiple infectious disease indications.
